Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00996372 · ClinicalTrials.gov registry record · Phase 3
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
A Phase 3 study of Sexual Dysfunctions, Psychological, sponsored by Sprout Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 949
- Enrollment target
- 20
- Study locations
NCT00996372 is a Phase 3 study of Sexual Dysfunctions, Psychological that has completed, run by Sprout Pharmaceuticals. The registered enrollment target is 949 participants. The trial reports 20 study locations across 7 states.
The verdict
NCT00996372, a Phase 3 study of Sexual Dysfunctions, Psychological, has completed, sponsored by Sprout Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 949 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.
Conditions Studied
Interventions
- DRUG placebo
- DRUG flibanserin
Study Locations (20)
California
- 511.130.01030 Boehringer Ingelheim Investigational Site - Encinitas
- 511.130.01028 Boehringer Ingelheim Investigational Site - Fair Oaks
- 511.130.01037 Boehringer Ingelheim Investigational Site - Irvine
- 511.130.01022 Boehringer Ingelheim Investigational Site - Sacramento
- 511.130.01035 Boehringer Ingelheim Investigational Site - San Diego
- 511.130.01052 Boehringer Ingelheim Investigational Site - San Diego
- 511.130.01016 Boehringer Ingelheim Investigational Site - Torrance
- 511.130.01021 Boehringer Ingelheim Investigational Site - Vista
- 511.130.01051 Boehringer Ingelheim Investigational Site - Westlake Village
Alabama
- 511.130.01074 Boehringer Ingelheim Investigational Site - Birmingham
- 511.130.01046 Boehringer Ingelheim Investigational Site - Huntsville
- 511.130.01042 Boehringer Ingelheim Investigational Site - Mobile
Connecticut
- 511.130.01053 Boehringer Ingelheim Investigational Site - Farmington
- 511.130.01015 Boehringer Ingelheim Investigational Site - Groton
- 511.130.01041 Boehringer Ingelheim Investigational Site - New Britain
Arizona
- 511.130.01025 Boehringer Ingelheim Investigational Site - Phoenix
- 511.130.01073 Boehringer Ingelheim Investigational Site - Phoenix
Colorado
- 511.130.01071 Boehringer Ingelheim Investigational Site - Denver
Delaware
- 511.130.01064 Boehringer Ingelheim Investigational Site - Newark
District of Columbia
- 511.130.01062 Boehringer Ingelheim Investigational Site - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 949 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00996372
The ClinicalTrials.gov registry entry for NCT00996372 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 949 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sprout Pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sexual Dysfunctions, Psychological appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00996372 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Alabama, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00996372 about?
NCT00996372 is a clinical study titled "Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women". The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.
What is the current status of trial NCT00996372?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 949 participants. The study started on 2009-10. Estimated completion is 2011-03.
What conditions does trial NCT00996372 study?
This clinical trial studies the following conditions: Sexual Dysfunctions, Psychological.
What interventions are being tested in trial NCT00996372?
The interventions under investigation include: placebo (DRUG), flibanserin (DRUG).
Who is sponsoring clinical trial NCT00996372?
This trial is sponsored by Sprout Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00996372 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sexual Dysfunctions, Psychological
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.